OptiNose (OPTN) to Release Earnings on Thursday

OptiNose (NASDAQ:OPTN) is expected to be announcing its earnings results before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.67) per share and revenue of $21.02 million for the quarter.

OptiNose Price Performance

NASDAQ:OPTN opened at $5.27 on Tuesday. OptiNose has a fifty-two week low of $4.82 and a fifty-two week high of $31.50. The stock’s 50-day moving average is $5.96 and its two-hundred day moving average is $8.93. The stock has a market cap of $53.02 million, a PE ratio of -1.26 and a beta of -0.17.

Wall Street Analysts Forecast Growth

Several equities analysts have weighed in on OPTN shares. Lake Street Capital lowered their target price on OptiNose from $45.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, January 16th. Piper Sandler lowered their price target on OptiNose from $45.00 to $15.00 and set an “overweight” rating for the company in a research note on Wednesday, November 13th. Finally, HC Wainwright boosted their price target on OptiNose from $5.00 to $18.00 and gave the company a “buy” rating in a research note on Friday, January 3rd.

About OptiNose

OptiNose, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device.